[
  {
    "ts": null,
    "headline": "Thrivent Mid Cap Value Fund Q1 2025 Commentary",
    "summary": "For the quarter, Thrivent Mid Cap Value Fund underperformed its benchmark due to negative stock selection.",
    "url": "https://finnhub.io/api/news?id=6cdbf15c23489131c788c8729c9fb4b99effd034ad580ce4522c6476d14d9bd1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751414100,
      "headline": "Thrivent Mid Cap Value Fund Q1 2025 Commentary",
      "id": 135702249,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990350865/image_1990350865.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "For the quarter, Thrivent Mid Cap Value Fund underperformed its benchmark due to negative stock selection.",
      "url": "https://finnhub.io/api/news?id=6cdbf15c23489131c788c8729c9fb4b99effd034ad580ce4522c6476d14d9bd1"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts",
    "summary": "Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=eeef653cdec8fbedf4d770c0f1bc026729f236f74d25a828238a88200cb40c85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751406304,
      "headline": "Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts",
      "id": 135699805,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=eeef653cdec8fbedf4d770c0f1bc026729f236f74d25a828238a88200cb40c85"
    }
  },
  {
    "ts": null,
    "headline": "A Promising Depression Drug Works. Psychedelics Are Back.",
    "summary": "Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of biotechs working on psychedelic medicines, after years of disappointments.  Just as top Trump administration health officials have begun to show a more receptive attitude to psychedelics, atai Life Sciences and Beckley Psytech said Tuesday that patients with difficult-to-treat depression symptoms who took Beckley’s drug BPL-003 saw improvement in an eight-week trial.  Atai is in the process of acquiring Beckley.",
    "url": "https://finnhub.io/api/news?id=770c61a8b07ce3e56e4e9754ab94701104385588f0e2f40d2b104e876b12305b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751396760,
      "headline": "A Promising Depression Drug Works. Psychedelics Are Back.",
      "id": 135697986,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of biotechs working on psychedelic medicines, after years of disappointments.  Just as top Trump administration health officials have begun to show a more receptive attitude to psychedelics, atai Life Sciences and Beckley Psytech said Tuesday that patients with difficult-to-treat depression symptoms who took Beckley’s drug BPL-003 saw improvement in an eight-week trial.  Atai is in the process of acquiring Beckley.",
      "url": "https://finnhub.io/api/news?id=770c61a8b07ce3e56e4e9754ab94701104385588f0e2f40d2b104e876b12305b"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 300-point rally highlighted by gains in Amgen, Merck shares",
    "summary": "Dow's 300-point rally highlighted by gains in Amgen, Merck shares",
    "url": "https://finnhub.io/api/news?id=d71523d544b94030d53eb6b87630c8a93b7a7ac763b72501532ba7fd0a8134ed",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751368440,
      "headline": "Dow's 300-point rally highlighted by gains in Amgen, Merck shares",
      "id": 135729800,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dow's 300-point rally highlighted by gains in Amgen, Merck shares",
      "url": "https://finnhub.io/api/news?id=d71523d544b94030d53eb6b87630c8a93b7a7ac763b72501532ba7fd0a8134ed"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?",
    "summary": "Sector ETF report for IHE",
    "url": "https://finnhub.io/api/news?id=4e28bd1a7cc07dd3a226662596ba23d4c0314a0db01a1800587eee6dccc2f9fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751365206,
      "headline": "Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?",
      "id": 135692453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Sector ETF report for IHE",
      "url": "https://finnhub.io/api/news?id=4e28bd1a7cc07dd3a226662596ba23d4c0314a0db01a1800587eee6dccc2f9fb"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?",
    "summary": "Sector ETF report for FHLC",
    "url": "https://finnhub.io/api/news?id=2bb96508dd28b29f360489c0f4247aefc4d31170870fba8c025ac3c486b232c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751365206,
      "headline": "Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?",
      "id": 135693887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Sector ETF report for FHLC",
      "url": "https://finnhub.io/api/news?id=2bb96508dd28b29f360489c0f4247aefc4d31170870fba8c025ac3c486b232c3"
    }
  },
  {
    "ts": null,
    "headline": "Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?",
    "summary": "Style Box ETF report for HDV",
    "url": "https://finnhub.io/api/news?id=38cab2ac4f6c1893fe2ba311c51cf2ebae7edae9fa3142513956327f00ecdf76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751365204,
      "headline": "Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?",
      "id": 135693645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Style Box ETF report for HDV",
      "url": "https://finnhub.io/api/news?id=38cab2ac4f6c1893fe2ba311c51cf2ebae7edae9fa3142513956327f00ecdf76"
    }
  }
]